These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1019 related articles for article (PubMed ID: 33951360)

  • 21. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
    Dorman SE; Savic RM; Goldberg S; Stout JE; Schluger N; Muzanyi G; Johnson JL; Nahid P; Hecker EJ; Heilig CM; Bozeman L; Feng PJ; Moro RN; MacKenzie W; Dooley KE; Nuermberger EL; Vernon A; Weiner M;
    Am J Respir Crit Care Med; 2015 Feb; 191(3):333-43. PubMed ID: 25489785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
    Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
    Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
    Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
    Belknap R; Holland D; Feng PJ; Millet JP; Caylà JA; Martinson NA; Wright A; Chen MP; Moro RN; Scott NA; Arevalo B; Miró JM; Villarino ME; Weiner M; Borisov AS;
    Ann Intern Med; 2017 Nov; 167(10):689-697. PubMed ID: 29114781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
    Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
    Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.
    Menzies D; Adjobimey M; Ruslami R; Trajman A; Sow O; Kim H; Obeng Baah J; Marks GB; Long R; Hoeppner V; Elwood K; Al-Jahdali H; Gninafon M; Apriani L; Koesoemadinata RC; Kritski A; Rolla V; Bah B; Camara A; Boakye I; Cook VJ; Goldberg H; Valiquette C; Hornby K; Dion MJ; Li PZ; Hill PC; Schwartzman K; Benedetti A
    N Engl J Med; 2018 Aug; 379(5):440-453. PubMed ID: 30067931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
    Conde MB; Efron A; Loredo C; De Souza GR; Graça NP; Cezar MC; Ram M; Chaudhary MA; Bishai WR; Kritski AL; Chaisson RE
    Lancet; 2009 Apr; 373(9670):1183-9. PubMed ID: 19345831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
    Zhang M; Li SY; Rosenthal IM; Almeida DV; Ahmad Z; Converse PJ; Peloquin CA; Nuermberger EL; Grosset JH
    Am J Respir Crit Care Med; 2011 May; 183(9):1254-61. PubMed ID: 21330452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
    Zhang T; Zhang M; Rosenthal IM; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2009 Dec; 180(11):1151-7. PubMed ID: 19729664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
    Swindells S; Ramchandani R; Gupta A; Benson CA; Leon-Cruz J; Mwelase N; Jean Juste MA; Lama JR; Valencia J; Omoz-Oarhe A; Supparatpinyo K; Masheto G; Mohapi L; da Silva Escada RO; Mawlana S; Banda P; Severe P; Hakim J; Kanyama C; Langat D; Moran L; Andersen J; Fletcher CV; Nuermberger E; Chaisson RE;
    N Engl J Med; 2019 Mar; 380(11):1001-1011. PubMed ID: 30865794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.
    Benator D; Bhattacharya M; Bozeman L; Burman W; Cantazaro A; Chaisson R; Gordin F; Horsburgh CR; Horton J; Khan A; Lahart C; Metchock B; Pachucki C; Stanton L; Vernon A; Villarino ME; Wang YC; Weiner M; Weis S;
    Lancet; 2002 Aug; 360(9332):528-34. PubMed ID: 12241657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.
    Dorman SE; Goldberg S; Stout JE; Muzanyi G; Johnson JL; Weiner M; Bozeman L; Heilig CM; Feng PJ; Moro R; Narita M; Nahid P; Ray S; Bates E; Haile B; Nuermberger EL; Vernon A; Schluger NW;
    J Infect Dis; 2012 Oct; 206(7):1030-40. PubMed ID: 22850121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
    Villarino ME; Scott NA; Weis SE; Weiner M; Conde MB; Jones B; Nachman S; Oliveira R; Moro RN; Shang N; Goldberg SV; Sterling TR; ;
    JAMA Pediatr; 2015 Mar; 169(3):247-55. PubMed ID: 25580725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
    Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.
    Feng Z; Miao Y; Peng Y; Sun F; Zhang Y; Li R; Ge S; Chen X; Song L; Li Y; Wang X; Zhang W
    BMC Infect Dis; 2023 May; 23(1):300. PubMed ID: 37158831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Adherence for 12 Weekly Doses of Isoniazid and Rifapentine for Pediatric Tuberculosis Infection.
    Cruz AT; Starke JR
    Pediatr Infect Dis J; 2016 Jul; 35(7):811-3. PubMed ID: 27088582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
    Tasneen R; Garcia A; Converse PJ; Zimmerman MD; Dartois V; Kurbatova E; Vernon AA; Carr W; Stout JE; Dooley KE; Nuermberger EL
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0239821. PubMed ID: 35315690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
    Nuermberger E; Tyagi S; Williams KN; Rosenthal I; Bishai WR; Grosset JH
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1452-6. PubMed ID: 16151038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.